Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaran Apold

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|November 22, 2005
[Hereditary breast cancer]Pål Møller, Lovise Maehle, Jaran Apold
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|August 18, 2006
[Handling of hereditary intestinal cancer]Pål Møller, Astrid Stormorken, Jaran Apold
Hereditary Cancer in Clinical Practice|September 4, 2009
No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriersPål Møller, Lovise Maehle, Neal Clark, et al.
Disease Markers|February 6, 2004
Haplotype analysis of Norwegian and Swedish patients with acute intermittent porphyria (AIP): Extreme haplotype heterogeneity for the mutation R116WKjersti Tjensvoll, Ove Bruland, Ylva Floderus, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2008
Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysisJan Norum, Anne Irene Hagen, Lovise Maehle, et al.
Hereditary Cancer in Clinical Practice|April 16, 2009
Survival in Norwegian BRCA1 mutation carriers with breast cancerAnne Irene Hagen, Steinar Tretli, Lovise Maehle, et al.
Hereditary Cancer in Clinical Practice|March 13, 2010
Germline PTEN mutations are rare and highly penetrantCecilie F Rustad, Merete Bjørnslett, Ketil R Heimdal, et al.
Hereditary Cancer in Clinical Practice|February 26, 2010
High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective seriesPål Møller, Lovise Mæhle, Lars F Engebretsen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2007
Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriersPål Møller, Anne Irene Hagen, Jaran Apold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriersLovise Maehle, Jaran Apold, Torbjørn Paulsen, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|November 22, 2005
[Hereditary breast cancer]Pål Møller, Lovise Maehle, Jaran Apold
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|August 18, 2006
[Handling of hereditary intestinal cancer]Pål Møller, Astrid Stormorken, Jaran Apold
Hereditary Cancer in Clinical Practice|September 4, 2009
No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriersPål Møller, Lovise Maehle, Neal Clark, et al.
Disease Markers|February 6, 2004
Haplotype analysis of Norwegian and Swedish patients with acute intermittent porphyria (AIP): Extreme haplotype heterogeneity for the mutation R116WKjersti Tjensvoll, Ove Bruland, Ylva Floderus, et al.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2008
Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysisJan Norum, Anne Irene Hagen, Lovise Maehle, et al.
Hereditary Cancer in Clinical Practice|April 16, 2009
Survival in Norwegian BRCA1 mutation carriers with breast cancerAnne Irene Hagen, Steinar Tretli, Lovise Maehle, et al.
Hereditary Cancer in Clinical Practice|March 13, 2010
Germline PTEN mutations are rare and highly penetrantCecilie F Rustad, Merete Bjørnslett, Ketil R Heimdal, et al.
Hereditary Cancer in Clinical Practice|February 26, 2010
High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective seriesPål Møller, Lovise Mæhle, Lars F Engebretsen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2007
Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriersPål Møller, Anne Irene Hagen, Jaran Apold, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2008
High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriersLovise Maehle, Jaran Apold, Torbjørn Paulsen, et al.
Pageof 2